Clinical efficacy of α4 integrin block with natalizumab in ankylosing spondylitis

Ann Rheum Dis. 2016 Nov;75(11):2053-2054. doi: 10.1136/annrheumdis-2016-209749. Epub 2016 Aug 23.

Authors

Francesco Ciccia¹, Aroldo Rizzo², Giuliana Guggino¹, Rodolfo Bignone³, Massimo Galia³, Giovanni Triolo¹

Affiliations

¹ Department of Rheumatology, University of Palermo, Palermo, Italy.
² Department of Pathology, Azienda Ospedaliera Villa Sofia-Cervello, Palermo, Italy.
³ Department of Radiology, University of Palermo, Palermo, Italy.

PMID: 27553212
DOI: 10.1136/annrheumdis-2016-209749

No abstract available

Keywords: Inflammation; Spondyloarthritis; Treatment.

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Biopsy, Needle
Follow-Up Studies
Humans
Immunohistochemistry
Integrin alpha4 / drug effects*
Integrin alpha4 / immunology
Lumbosacral Region
Magnetic Resonance Imaging / methods
Male
Middle Aged
Molecular Targeted Therapy
Natalizumab / therapeutic use*
Radiography / methods
Risk Assessment
Severity of Illness Index
Spondylitis, Ankylosing / diagnostic imaging*
Spondylitis, Ankylosing / drug therapy*
Spondylitis, Ankylosing / immunology
Treatment Outcome

Substances

Antibodies, Monoclonal
Natalizumab
Integrin alpha4